NTCP binder peptide WL4|

Cas No.:
Chemical Name:	(3S,6S,9S,12S,15S,18R,24S,27S,30S,33S,36S,39S,44aS)-6-((1H-imidazol-4-yl)methyl)-33,39-bis((1H-indol-3-yl)methyl)-3-(2-amino-2-oxoethyl)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-9-benzyl-30,36-di((S)-sec-butyl)-12,15,24-tris(4-hydroxybenzyl)-27-isopr
SMILES:	C1CC(=O)N[C@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](C(C)C)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC2C3=C(NC=2)C=CC=C3)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC2C3=C(NC=2)C=CC=C3)C(=O)N2CCC[C@@]2([H])S(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC2=CNC=N2)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)
Formula:	C₉₉H₁₂₂N₂₀O₂₀S
M.Wt:	1944.245
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=42 nM), reduces HBs antigen levels in culture supernatants with IC50 of 0.66 uM; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC47304	AB-729	AB-729, a nucleoside analogue, is an RNA interference (RNAi). AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR). AB-729 inhibits viral replication and reduces HBV antigens.
DC47248	Vebicorvir	Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
DC47052	Tenofovir amibufenamide	Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
DC47037	Firzacorvir	Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC50 < 1 μΜ.
DC45956	LPRP-Et-97543	LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research.
DC45517	Schisanwilsonin C	Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.
DC45405	Chamaechromone	Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.
DC44116	HBV-IN-4	HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies.
DC42271	Sophoranol	Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
DC40060	LB80317	LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.